Pharmazz Inc.

Pharmazz Inc. is dedicated to saving lives through innovative pharmaceutical manufacturing. Specializing in critical care medicine and neurology, Pharmazz Inc. focuses on developing and marketing novel products that address critical unmet needs. The company has achieved significant milestones, including FDA approval for phase III INDs for Centhaquine as an agent for hypovolemic shock and Sovateltide for cerebral ischemic stroke. Furthermore, Pharmazz Inc. has secured marketing authorization in India for both Centhaquine and Sovateltide as first-in-class drug molecules, demonstrating its commitment to advancing healthcare solutions globally.

Located at its primary address at 50 West 75th Street, Suite 105, Willowbrook, IL, 60527, US, Pharmazz Inc. continues to expand its reach and impact through strategic partnerships and innovative research. With additional facilities at H-6, Site-C, Surajpur Industrial Area, Greater Noida, Uttar Pradesh 201307, IN, and H-31, Site C, Surajpur, Industrial Area, Greater Noida, Uttar Pradesh 201307, IN, the company maintains a strong presence in key markets, ensuring accessibility and distribution of its life-saving medications.

Pharmazz Inc. remains committed to pushing the boundaries of pharmaceutical innovation and improving patient outcomes worldwide. For more information on Pharmazz Inc.'s products and initiatives, please visit www.pharmazz.com. We invite the manager of Pharmazz Inc. to create a customized and exclusive company showcase and product listing on our platform to further enhance their market presence.